Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 9/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4044287 | 1.00 | CTSK (0.61) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL2049277 | 1.00 | CTSK (0.61) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL1467769 | 0.91 | CA1 (0.71) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL3487489 | 0.91 | CA1 (0.71) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL3487968 | 0.91 | CA1 (0.71) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL6187601 | 0.90 | CTSK (0.56) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL30175163 | 0.90 | CA1 (0.66) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL5556389 | 0.90 | CA1 (0.66) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL19024479 | 0.89 | HSD11B1 (0.54) | CTSKHSD11B1CYP2C9CA1CA2 | |
| SCHEMBL1649898 | 0.88 | CTSK (0.61) | CTSKHSD11B1CYP2C9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191473-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | Esanex, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040809-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| EP-2685990-A1 | COMBINATION OF ANTI-CLUSTERIN OLIGONUCLEOTIDE WITH HSP90 INHIBITOR FOR THE TREATMENT OF PROSTATE CANCER | The University Of British Columbia (CA) | 2014-01-22 | — | — | EP | claimed |
| WO-2012123823-A1 | COMBINATION OF ANTI-CLUSTERIN OLIGONUCLEOTIDE WITH HSP90 INHIBITOR FOR THE TREATMENT OF PROSTATE CANCER | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-09-20 | — | — | WO | claimed |
| WO-2008156831-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | claimed |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-07-13 | — | — | US | disclosed |
| WO-2023119233-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2023-06-29 | — | — | WO | disclosed |
| EP-3313453-A1 | METHOD FOR IMAGING ARTHRITIS | Guy's And St Thomas' Nhs Foundation Trust (GB) | 2018-05-02 | — | — | EP | disclosed |
| EP-3191473-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | Esanex, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016207636-A1 | METHOD FOR IMAGING ARTHRITIS | GUY'S AND ST THOMAS' HOSPITAL NHS FOUNDATION TRUST (GB) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016040809-A1 | INDAZOLYL- AND INDOLYL-BENZAMIDE DERIVATIVES | ESANEX, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2911771-A1 | DROPLET INTERFACES | Oxford Nanopore Technologies Limited (GB) | 2015-09-02 | — | — | EP | disclosed |
| US-7049323-B2 | Amidoheterocycles as modulators of the melanocortin-4 receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-23 | — | — | US | disclosed |
| WO-2005049617-A1 | PYRAZOLOPYRIMIDINES | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20040224901-A1 | Amidoheterocycles as modulators of the melanocortin-4 receptor | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-11 | — | — | US | disclosed |
| EP-0394685-A2 | (S)-7-(3-Amino-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid | WARNER-LAMBERT COMPANY (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4916141-A | ANTIBACTERIAL | WARNER-LAMBERT COMPANY (US) | 1990-04-10 | — | — | US | disclosed |
| US-4851418-A | Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0304087-A2 | Quinolone and naphthyridine antibacterial agents containing an alpha-amino acid in the side chain of the 7-substituent | WARNER-LAMBERT COMPANY (US) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | CTSK 146/4885HSD11B1 491/4885CYP2C9 76/4885 |
| US-20230219973-A1 | DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOF | USP7, USP28, USP1 | CTSK 368/4885HSD11B1 2415/4885CYP2C9 3896/4885 |
| US-20040224901-A1 | Amidoheterocycles as modulators of the melanocortin-4 receptor | MC4R, MC1R, MC3R | CTSK 3614/4885HSD11B1 1779/4885CYP2C9 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.